Clinical Trial Results:
Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infants in Republic of South Africa
Summary
|
|
EudraCT number |
2018-004708-21 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
13 Mar 2019
|
Results information
|
|
Results version number |
v1 |
This version publication date |
28 Oct 2019
|
First version publication date |
28 Oct 2019
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
A3L44
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02817451 | ||
WHO universal trial number (UTN) |
U1111-1161-2610 | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur
|
||
Sponsor organisation address |
14 Espace Henry Vallée, Lyon, France, 69007
|
||
Public contact |
Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
|
||
Scientific contact |
Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Aug 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Mar 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
- To evaluate the immunogenicity of the study vaccine 1 month after the 3-dose primary series in Human Immunodeficiency Virus (HIV)-exposed infected and in HIV-exposed uninfected infants.
- To describe the persistence of all antibodies before receipt of the booster vaccination in HIV-exposed infected and in HIV-exposed uninfected infants.
- To evaluate the immunogenicity of the study vaccine 1 month after the booster dose in HIV-exposed infected and in HIV-exposed uninfected infants.
|
||
Protection of trial subjects |
Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment was also available on site in case of any immediate allergic reactions.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
14 Jul 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
South Africa: 64
|
||
Worldwide total number of subjects |
64
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
64
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Study was conducted at 1 centre in South Africa from 14 July 2016 to 13 March 2019. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
A total of 64 subjects who met all of the inclusion criteria and none of the exclusion criteria were enrolled and vaccinated in the study. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Overall study (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
HIV-Exposed Infected Subjects | ||||||||||||||||||||||||
Arm description |
Subjects identified as polymerase chain reaction (PCR) positive for HIV received 3 doses of primary vaccination with Diphtheria (D), tetanus (T), pertussis (2-component acellular) (aP), recombinant Hepatitis B Hansenula polymorpha (Hep B) and inactivated poliovirus vaccine (IPV) adsorbed, and Haemophilus influenzae type b (Hib) (DTaP-IPV-HB-PRP-T) combined vaccine at 6, 10, and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
DTaP-IPV-HB-PRP-T combined vaccine
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
Hexaxim®
|
||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||
Dosage and administration details |
0.5 mL (millilitre), intramuscular injection into the anterolateral area of the right thigh.
|
||||||||||||||||||||||||
Arm title
|
HIV-Exposed Uninfected Subjects | ||||||||||||||||||||||||
Arm description |
Subjects identified as HIV-exposed during pregnancy but uninfected received 3 doses of primary vaccination with DTaP-IPV-HB-PRP-T combined vaccine at 6, 10, and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
DTaP-IPV-HB-PRP-T combined vaccine
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
Hexaxim®
|
||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular injection into the anterolateral area of the right thigh.
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
HIV-Exposed Infected Subjects
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects identified as polymerase chain reaction (PCR) positive for HIV received 3 doses of primary vaccination with Diphtheria (D), tetanus (T), pertussis (2-component acellular) (aP), recombinant Hepatitis B Hansenula polymorpha (Hep B) and inactivated poliovirus vaccine (IPV) adsorbed, and Haemophilus influenzae type b (Hib) (DTaP-IPV-HB-PRP-T) combined vaccine at 6, 10, and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
HIV-Exposed Uninfected Subjects
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects identified as HIV-exposed during pregnancy but uninfected received 3 doses of primary vaccination with DTaP-IPV-HB-PRP-T combined vaccine at 6, 10, and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
HIV-Exposed Infected Subjects
|
||
Reporting group description |
Subjects identified as polymerase chain reaction (PCR) positive for HIV received 3 doses of primary vaccination with Diphtheria (D), tetanus (T), pertussis (2-component acellular) (aP), recombinant Hepatitis B Hansenula polymorpha (Hep B) and inactivated poliovirus vaccine (IPV) adsorbed, and Haemophilus influenzae type b (Hib) (DTaP-IPV-HB-PRP-T) combined vaccine at 6, 10, and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | ||
Reporting group title |
HIV-Exposed Uninfected Subjects
|
||
Reporting group description |
Subjects identified as HIV-exposed during pregnancy but uninfected received 3 doses of primary vaccination with DTaP-IPV-HB-PRP-T combined vaccine at 6, 10, and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects with Anti-Pertussis Toxoid (PT) and Anti-Filamentous Hemagglutinin (FHA) Antibody (Ab) Concentrations less than equal to (>=) Lower Limit of Quantification (LLOQ) and >=4*LLOQ at Baseline [1] | ||||||||||||||||||||||||
End point description |
Anti-PT and anti-FHA Ab concentrations were determined in terms of endotoxin units per millilitre (EU/mL). Analysis was performed on per-protocol analysis set which was a subset of the full analysis set (FAS) that included all subjects who had received at least one dose of study vaccine.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Day 0 (baseline)
|
||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Geometric Means of Anti-Pertussis Toxoid and Anti-Filamentous Hemagglutinin Antibody Concentrations at Baseline [2] | ||||||||||||||||||
End point description |
Anti-PT and anti-FHA Ab levels were measured by enzyme-linked immunosorbent assay (ELISA) and anti-PT and anti-FHA Ab concentrations were determined in terms of EU/mL. Analysis was performed on per protocol analysis set.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Day 0 (baseline)
|
||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Geometric Means of Antibody Titers/Concentrations After Primary Series Vaccination [3] | |||||||||||||||||||||||||||||||||||||||
End point description |
Anti-diphtheria Ab levels were measured by a toxin neutralisation test. Anti-tetanus, anti-PT and anti-FHA Ab levels were measured by ELISA. Anti-poliovirus types 1, 2, and 3 Ab levels were measured by neutralisation assay. Anti-Hep B Ab levels were measured by VITROS ECi/ECiQ Immunodiagnostic system using chemiluminescence detection technology. Anti-polyribosylribitol phosphate (PRP) Ab levels were measured using a Farr-type radioimmunoassay (RIA). Ab concentrations were determined as: anti-diphtheria >=0.01 international units (IU)/mL, >=0.1 IU/mL, 1.0 IU/mL, anti-tetanus >=0.01 IU/mL, >=0.1 IU/mL, and >=1.0 IU/mL, anti-PT and anti-FHA EU/mL, anti-PRP >=0.15 microgram (mcg)/mL, >=1.0 mcg/mL, anti-Poliovirus types 1, 2, and 3 Ab titers >=8 (1/dilution [dil]), Anti-Hep B >=10 milli (m) IU/mL, and >=100 mIU/mL. Analysis was performed on per-protocol analysis set. Here, ‘n’ signifies subjects with available data for each specified category.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 90 (1 month after third dose)
|
|||||||||||||||||||||||||||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Seroprotection After Primary Series Vaccination [4] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Seroprotection was determined as: anti-diptheria Ab concentrations >=0.01 IU/mL, >=0.1 IU/mL, and >=1.0 IU/mL, anti-tetanus Ab concentrations >=0.01 IU/mL, >=0.1 IU/mL, and >=1.0 IU/mL, anti-PT and anti-FHA Ab concentrations EU/mL (>=LLOQ and >=4*LLOQ), anti-PRP Ab concentrations >=0.15 mcg/mL and >=1.0 mcg/mL, anti-poliovirus 1, 2, and 3 Ab titers >=8 (1/dil), anti-Hep B Ab concentrations >=10 mIU/mL and >=100 mIU/mL. Analysis was performed on per-protocol analysis set. Here, ‘n’ signifies subjects with available data for each specified category.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 90 (1 month after third dose)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects with Vaccine Response or Seroconversion After Primary Series Vaccination [5] | ||||||||||||||||||||||||
End point description |
Vaccine response was defined for anti-PT and anti-FHA as Ab post-Dose 3 concentrations >=4*LLOQ, if pre-Dose (Day 0) Ab concentration is <4*LLOQ or 1 month after third dose (Day 90) concentrations >= pre-Dose Ab concentrations if pre-Dose (Day 0) concentrations >=4*LLOQ. Seroconversion for anti-PT and anti-FHA was defined as >=4-fold Ab concentrations increase from pre-Dose (Day 0) to 1 month after third dose (Day 90). Analysis was performed on per-protocol analysis set.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Day 0 (baseline), Day 90 (1 month after third dose)
|
||||||||||||||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Geometric Means of Antibody Titers/Concentrations After Booster Vaccination [6] | |||||||||||||||||||||||||||||||||||||||
End point description |
Anti-diphtheria Ab levels were measured by toxin neutralisation test. Anti-tetanus, anti-PT, and anti-FHA Ab levels were measured by ELISA. Anti-poliovirus types 1, 2, and 3 Ab levels were measured by neutralisation assay. Anti-Hep B Ab levels were measured by VITROS ECi/ECiQ Immunodiagnostic system using chemiluminescence detection technology. Anti-PRP Ab levels were measured using a Farr-type RIA. Ab concentrations: anti-diphtheria >=0.01 IU/mL, >=0.1 IU/mL, >=1.0 IU/mL, anti-tetanus >=0.01 IU/mL, >=0.1 IU/mL, and >=1.0 IU/mL, anti-PT and anti-FHA EU/mL, anti-PRP >=0.15 mcg/mL, >=1.0 mcg/mL, anti-poliovirus 1, 2, and 3 Ab titers >=8 (1/dil), anti-Hep B >=10 mIU/mL, and >=100 mIU/mL. Analysis was performed on booster per-protocol analysis set which included subjects who received the booster dose of the vaccine, and with at least one antibody titer available pre-booster dose or one month post-booster.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 420 (1 month after booster vaccination)
|
|||||||||||||||||||||||||||||||||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Seroprotection After Booster Vaccination [7] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Seroprotection: anti-diphtheria Ab concentrations >=0.01 IU/mL, >=0.1 IU/mL, and >=1.0 IU/mL, anti-tetanus Ab concentrations >=0.01 IU/mL, >=0.1 IU/mL, and >=1.0 IU/mL, anti-PT and anti-FHA Ab concentrations EU/mL (>=LLOQ and >=4*LLOQ), anti-PRP Ab concentrations >=0.15 mcg/mL and >=1.0 mcg/mL, anti-poliovirus 1, 2, and 3 Ab titers >=8 (1/dil), and anti-Hep B Ab concentrations >=10 mIU/mL and >=100 mIU/mL. Analysis was performed on booster per-protocol analysis Set.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 420 (1 month after booster vaccination)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects With Vaccine Response or Seroconversion After Booster Vaccination [8] | ||||||||||||||||||||||||
End point description |
Vaccine response was defined for anti-PT and anti-FHA as >=4 fold Ab concentrations increase from pre-dose (Day 0) to 1 month after booster dose (Day 420), if pre-Dose (Day 0) Ab concentrations <4*LLOQ; or >=2 fold Ab concentrations increase from pre- dose (Day 0) to 1 month after booster dose (Day 420), if pre-dose (Day 0) Ab concentrations >=4*LLOQ. Seroconversion was defined for anti-PT and anti-FHA as >=4 fold Ab concentrations increase from pre-dose (Day 0) to 1 month after booster dose. Analysis was performed on booster per-protocol analysis set.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Day 0 (baseline), Day 420 (1 month after booster vaccination)
|
||||||||||||||||||||||||
Notes [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Number of Subjects With Booster Response After Booster Vaccination [9] | ||||||||||||||||||
End point description |
Booster response was defined for anti-PT and anti-FHA as >=4 fold Ab concentrations increase from pre-booster (Day 390) to 1 month after booster dose (Day 420), if pre-booster Ab concentrations <4*LLOQ; or >=2 fold Ab concentrations increase from pre-booster (Day 390) to 1 month after booster dose (Day 390) if pre-Booster Ab concentrations >=4*LLOQ. Analysis was performed on booster per-protocol analysis set.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Day 390 (pre-booster), Day 420 (1 month after booster dose)
|
||||||||||||||||||
Notes [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Immediate Unsolicited Adverse Events (AE) After Primary Series Vaccination | ||||||||||||
End point description |
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Analysis was performed on safety analysis set which included subjects who had received at least one dose of study vaccine.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Within 30 minutes after vaccination
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Solicited Injections Site or Systemic Reactions After Primary Series Vaccination | |||||||||||||||||||||||||||||||||||||||
End point description |
A solicited reaction is an adverse reaction observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions: injection site tenderness, erythema, and swelling. Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability. Analysis was performed on safety analysis set. Here, number of subjects analysed signifies subjects evaluable for this end-point.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 7 days after vaccination
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Number of Subjects With Unsolicited Adverse Events After Primary Series Vaccination | |||||||||||||||||||||
End point description |
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. An unsolicited non-serious AE is an unsolicited AE excluding serious adverse events (SAEs). Systemic AEs are all AEs that are not injection site reactions. They therefore include systemic manifestations such as headache, fever, as well as localized or topical manifestations that are not associated with the vaccination site. Analysis was performed on safety analysis set.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Within 30 days after vaccination
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Serious Adverse Events During the Study | ||||||||||||
End point description |
An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. Analysis was performed on safety analysis set.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 0 to Day 420
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Immediate Unsolicited Adverse Events After Booster Vaccination | ||||||||||||
End point description |
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. Analysis was performed on booster safety analysis set which included the subjects who had received the booster dose of study vaccine.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Within 30 minutes after booster vaccination
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Solicited Injection Site or Systemic Reactions After Booster Vaccination | ||||||||||||||||||||||||||||||||||||||||||
End point description |
A solicited reaction is an adverse reaction observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions: tenderness, erythema, swelling, and extensive limb swelling. Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability. Analysis was performed on booster safety analysis set.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 7 days after booster vaccination
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Number of Subjects With Unsolicited Adverse Events After Booster Vaccination | |||||||||||||||||||||
End point description |
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. An unsolicited non-serious AE is an unsolicited AE excluding SAEs. Systemic AEs are all AEs that are not injection site reactions. They therefore include systemic manifestations such as headache, fever, as well as localized or topical manifestations that are not associated with the vaccination site. Analysis was performed on booster safety analysis set.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Within 30 days after booster vaccination
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Solicited reactions (SR): collected up to Day 7 after each vaccination, non-serious unsolicited adverse events were collected up to Day 30 after each vaccination. SAEs: throughout the trial (up to 30 days after primary series and booster vaccination).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
SR: AE prelisted in eCRF, considered related to vaccination. SR was therefore, an adverse drug reaction observed, reported under conditions (symptom and onset) prelisted in eCRF. Unsolicited AE: an observed AE that does not fulfill conditions prelisted in eCRF in terms of diagnosis and/or onset post-vaccination. Analysis done on safety analysis set
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
HIV-Exposed Infected Subjects
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects identified as PCR positive for HIV received 3 doses of primary vaccination with DTaP-IPV-HB-PRP-T combined vaccine at 6, 10 and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
HIV-Exposed Uninfected Subjects
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects identified as HIV-exposed during pregnancy but uninfected received 3 doses of primary vaccination with DTaP-IPV-HB-PRP-T combined vaccine at 6, 10 and 14 weeks of age (Infant Series), followed by a booster dose approximately 12 months after the completion of the Infant Series (at 15 to 18 months of age). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
07 Dec 2015 |
Following amendment changes were made: the table of procedures were edited to more accurately represent the intentions found in the protocol, the schedule of visits was edited to more accurately represent the procedures to be followed at each visit, in Section 6.5 of the protocol, information was added to more clearly describe the process of screening subjects in this study, the tympanic route temperature was replaced by the axillary route temperature to be used in this study for determining temperature. Note that the oral route could also be used. |
||
12 Feb 2016 |
Following amendment changes were made: the exclusion criterion #7 was modified: the temperature was >=38.0 degree Celsius (°C) in lieu of >=37.4°C; the table of procedures was updated as follows: during the screening period, the demographic data of all the subjects were to be collected in the CRF, at Visit 1 (Day 0), the vaccination history of all the subjects’ mother was to be collected in the CRF, memory aid checked – Visit 5 was added with a cross checked at Visit 5 (Day 390), Visit 5 (booster vaccine injection) was mentioned according to Visit 3 (last vaccine injection), section 5.1.4 visit procedures of the protocol was updated according to the table of procedures. |
||
20 Oct 2016 |
Following amendment changes were made: the period of detection was extended to 6 weeks of age in lieu of 4 to 6 weeks of age, subject’s inclusion was modified, infants detected HIV+ outside the study screening process could be included, the screening criterion #2 was modified: self-reported or maternity-reported of HIV infection in the mother, not only documented proof HIV infection in the mother, the inclusion #1 and #3 were modified: infants born to an adult mother and aged 35 to 56 days (not 49 days) (between 5 and 8 weeks (not 7 weeks) of age) on the day of inclusion and born with a birth weight >=2.0 kg (not 2.5 kg), the table of procedure was updated according to the extension of the screening phase and the subject’s age at inclusion (inclusion criterion #1), the number of countries, where the product has been licensed, was modified: 104 countries in lieu of 78 countries, the visit procedures was updated according to the additional way of selection of subjects. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |